Analyst Ratings For Aldeyra Therapeutics Inc (NASDAQ:ALDX)
Today, Citigroup initiated coverage on Aldeyra Therapeutics Inc (NASDAQ:ALDX) with a Buy with a price target of $23.00.
There are 5 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Aldeyra Therapeutics Inc (NASDAQ:ALDX) is Buy with a consensus target price of $27.50 per share, a potential 175.00% upside.
Some recent analyst ratings include
- 12/4/2018-Aldeyra Therapeutics Inc (NASDAQ:ALDX) has coverage initiated with a Buy rating and $23.00 price target
- 11/14/2018-Aldeyra Therapeutics Inc (NASDAQ:ALDX) had its Buy rating reiterated by Cantor Fitzgerald with a $30.00 price target
- 4/9/2018-Aldeyra Therapeutics Inc (NASDAQ:ALDX) had its Hold rating reiterated by Cowen
- 3/1/2018-Aldeyra Therapeutics Inc (NASDAQ:ALDX) had its Buy rating reiterated by Seaport Global Securities
- On 9/19/2017 Life Sciences Maste Perceptive, Major Shareholder, bought 200,000 with an average share price of $7.25 per share and the total transaction amounting to $1,450,000.00.
- On 6/30/2017 Life Sciences Maste Perceptive, Major Shareholder, bought 296,007 with an average share price of $4.60 per share and the total transaction amounting to $1,361,632.20.
- On 2/17/2017 Martin Joseph Joyce, Director, bought 4,444 with an average share price of $4.50 per share and the total transaction amounting to $19,998.00.
- On 2/17/2017 Stephen J Tulipano, CFO, bought 3,333 with an average share price of $4.50 per share and the total transaction amounting to $14,998.50.
- On 2/17/2017 Todd C Brady, Insider, bought 22,223 with an average share price of $4.50 per share and the total transaction amounting to $100,003.50.
- On 2/14/2017 Perceptive Advisors Llc, Major Shareholder, bought 893,025 with an average share price of $4.50 per share and the total transaction amounting to $4,018,612.50.
- On 5/26/2016 Perceptive Advisors Llc, Major Shareholder, bought 700,000 with an average share price of $5.00 per share and the total transaction amounting to $3,500,000.00.
About Aldeyra Therapeutics Inc (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Recent Trading Activity for Aldeyra Therapeutics Inc (NASDAQ:ALDX)
Shares of Aldeyra Therapeutics Inc closed the previous trading session at 9,91 +0,65 7,02 % with 9.56 shares trading hands.